In Study @ , subjects received lenalidomide ( a single @ mg dose ) alone , the P-gp inhibitor quinidine ( @-@ mg twice-daily @ days ) plus lenalidomide ( on Day @ ) , the P-gp inhibitor/substrate temsirolimus ( a single @ mg dose ) alone , or lenalidomide plus temsirolimus .